A Forward Look, The Year Ahead - Featured Research on AMAG Pharmaceuticals, Inc. and Akorn, Inc.
(firmenpresse) - HONG KONG -- (Marketwire) -- 02/10/12 -- Today, introduced featured coverage of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and Akorn, Inc. (NASDAQ: AKRX). Full research reports are available to readers at: .
Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.
Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.
Bollinger Report screened and selected AMAG Pharmaceuticals, Inc. for its current position within the healthcare industry. AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The Company markets and sells Feraheme in the United States through its own commercial organization. A copy of this report featuring AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) is available at: .
Bollinger Report is featuring Akorn, Inc. for its changing role within the healthcare industry. Akorn, Inc. manufactures and markets a range of diagnostic and therapeutic ophthalmic pharmaceuticals, as well as niche hospital drugs and injectable pharmaceuticals. In addition, the Company has marketed and distributed vaccines purchased from outside sources. The Company operates in three segments: ophthalmic; hospital drugs and injectables, and contract services. To download researches and analysis on Akorn, Inc. (NASDAQ: AKRX) we welcome investors to visit: .
About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.
Contact:
Martin Schwartz
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.02.2012 - 14:00 Uhr
Sprache: Deutsch
News-ID 113348
Anzahl Zeichen: 0
contact information:
Town:
HONG KONG
Kategorie:
Investment Services & Trading
Diese Pressemitteilung wurde bisher 179 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"A Forward Look, The Year Ahead - Featured Research on AMAG Pharmaceuticals, Inc. and Akorn, Inc."
steht unter der journalistisch-redaktionellen Verantwortung von
Bollinger Report (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
